The key to treating cancer could be the body's own immune system
A new study in The New England Journal of Medicine, presented this weekend at the American Society of Clinical Oncology's annual conference in Chicago, found that two cancer drugs, when taken together, could shrink tumors in patients with advanced-stage melanoma.
In a trial of 945 worldwide patients, researchers found that combining ipilimumab and nivolumab, two drugs that work with the body's immune system, reduced the melanoma tumors of nearly 60 percent of patients. The combination, which spurred the immune system to fight cancer, also prevented melanoma from advancing for almost a year in more than half of the patients studied.
Over the course of a year, 58 percent of the study participants had their tumors shrink by at least a third while taking the two medicines. But while the researchers agree the results are promising, combining the medications also increased patients' side effects, and 36 percent of patients stopped the treatment because of the side-effects. The scientists behind the study are also still researching the immunotherapy treatment's survival rates.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Meghan DeMaria is a staff writer at TheWeek.com. She has previously worked for USA Today and Marie Claire.
-
A crowded field of Democrats is filling up the California governor’s raceIn the Spotlight Over a dozen Democrats have declared their candidacy
-
Nitazene is elusively raising opioid deathsThe explainer The drug is usually consumed accidentally
-
Can medical debt hurt your credit?The explainer The short answer is yes, though it depends on the credit scoring mode
-
Blue Origin launches Mars probes in NASA debutSpeed Read The New Glenn rocket is carrying small twin spacecraft toward Mars as part of NASA’s Escapade mission
-
Dinosaurs were thriving before asteroid, study findsSpeed Read The dinosaurs would not have gone extinct if not for the asteroid
-
SpaceX breaks Starship losing streak in 10th testspeed read The Starship rocket's test flight was largely successful, deploying eight dummy satellites during its hour in space
-
Rabbits with 'horns' sighted across Coloradospeed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's studySpeed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-offSpeed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet underseaSpeed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
New York plans first nuclear plant in 36 yearsSpeed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
